2025
Streamline: Retrospective Cohort Study of FMS-Like Tyrosine Kinase 3-Mutated Acute Myeloid Leukemia – Real-World Treatment Patterns and Clinical Outcomes of Patients in First Relapse or Refractory Diagnosis
Zeidan A, Yu R, Wang Y, Lan Z, Grinblatt D, Elsouda D, Spalding J, Block A, Touya M, Walker M, Pandya B. Streamline: Retrospective Cohort Study of FMS-Like Tyrosine Kinase 3-Mutated Acute Myeloid Leukemia – Real-World Treatment Patterns and Clinical Outcomes of Patients in First Relapse or Refractory Diagnosis. Acta Haematologica 2025, 1-12. PMID: 40228486, PMCID: PMC12112888, DOI: 10.1159/000545384.Peer-Reviewed Original ResearchAcute myeloid leukemiaReal-world overall survivalAcute myeloid leukemia diagnosisReal-world time to next treatmentTreatment patternsFLT3-TKIMyeloid leukemiaClinical outcomesMedian real-world overall survivalTime to next treatmentClinical outcomes of patientsFLT3 tyrosine kinase inhibitorsReal-world treatment patternsAcute myeloid leukemia patientsFMS-like tyrosine kinase 3R/R AML patientsHigh-intensity chemotherapyOutcomes of patientsRetrospective cohort studyTyrosine kinase 3Retrospective longitudinal studyFirst relapseOverall survivalAML patientsFLT3 mutations
2024
Toxicity and Efficacy of Isavuconazole Vs Voriconazole As Anti-Fungal Prophylaxis for Patients with Acute Myeloid Leukemia
Hunter C, Bewersdorf J, Mendez L, Podoltsev N, Zeidan A, Eighmy W, Roeder H, Malinis M, Shallis R. Toxicity and Efficacy of Isavuconazole Vs Voriconazole As Anti-Fungal Prophylaxis for Patients with Acute Myeloid Leukemia. Blood 2024, 144: 1480-1480. DOI: 10.1182/blood-2024-211250.Peer-Reviewed Original ResearchInvasive fungal infectionsAcute myeloid leukemiaAntifungal prophylaxisDiagnosed AMLDrug-drug interactionsTransaminase elevationVisual disturbancesRates of invasive fungal infectionsInvasive fungal infections incidenceBaseline ANCCD4 countMyeloid leukemiaAllogeneic stem cell transplantationAnti-fungal prophylaxisAcute myeloid leukemia diagnosisDuration of neutropeniaBaseline CD4 countLess-intensive therapyStem cell transplantationPatient baseline characteristicsSide effect profileCandida sppTriazole agentsWilcoxon rank sum testAntifungal voriconazole
2022
Patient‐centered communication tool for older patients with acute myeloid leukemia, their caregivers, and oncologists: A single‐arm pilot study
LoCastro M, Sanapala C, Wang Y, Jensen‐Battaglia M, Wittink M, Norton S, Klepin H, Richardson D, Mendler J, Liesveld J, Huselton E, O'Dwyer K, Cortes A, Rodriguez C, Dale W, Loh K. Patient‐centered communication tool for older patients with acute myeloid leukemia, their caregivers, and oncologists: A single‐arm pilot study. Cancer Medicine 2022, 12: 8581-8593. PMID: 36533397, PMCID: PMC10134384, DOI: 10.1002/cam4.5547.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaOlder patientsPerceived greater efficacyTreatment decisionsPrognostic awarenessPost-interventionMyeloid leukemiaPatient valuesOlder adultsFeasibility metricsCaregiversDiagnosed acute myeloid leukemiaRetention rateAcute myeloid leukemia diagnosisRecruitment ratesPerceived EfficacyPilot natureCommunication toolsOncologistsTreatment optionsSample sizeGreater efficacyPatientsLeukemiaTreatment
2021
Clinical decision rule for obtaining peripheral blood cultures in febrile oncology patients
Gorfinkel L, Hansen CE, Teng W, Shabanova V, Prozora S, Rodwin R, Qadri U, Manghi T, Emerson B, Riera A. Clinical decision rule for obtaining peripheral blood cultures in febrile oncology patients. Pediatric Blood & Cancer 2021, 69: e29519. PMID: 34939321, DOI: 10.1002/pbc.29519.Peer-Reviewed Original ResearchConceptsPediatric emergency departmentPeripheral blood culturesPediatric oncology patientsFebrile oncology patientsClinical decision ruleOncology patientsBlood culturesBloodstream infectionsPositive peripheral blood cultureDiagnostic prediction toolsInternal validationRetrospective chart reviewAcute myeloid leukemia diagnosisRecent systematic reviewClinical prediction modelReceiver operator curveVasopressor supportActive therapyChart reviewDerivation cohortIndependent predictorsEmergency departmentPatientsSystematic reviewOperator curveFlexible Modeling of Net Survival and Cure by AML Subtype and Age: A French Population-Based Study from FRANCIM
Mounier M, Romain G, Callanan M, Alla A, Boussari O, Maynadié M, Colonna M, Jooste V. Flexible Modeling of Net Survival and Cure by AML Subtype and Age: A French Population-Based Study from FRANCIM. Journal Of Clinical Medicine 2021, 10: 1657. PMID: 33924506, PMCID: PMC8069423, DOI: 10.3390/jcm10081657.Peer-Reviewed Original ResearchTherapy-related AMLYounger patientsAML subtypesNet survivalAML patientsAcute myeloid leukemia diagnosisDiagnosis of AMLAcute myelomonocytic leukemiaAcute promyelocytic leukemiaYears of ageRecurrent cytogenetic abnormalitiesFrench populationMedian survivalMore patientsBetter prognosisPoor survivalAML subsetsMyelomonocytic leukemiaPromyelocytic leukemiaSex disparitiesPatientsOlder menCytogenetic abnormalitiesMonocytic leukemiaAge groups
2015
Myelodysplastic Syndromes and Acute Myeloid Leukemia in Prostate Cancer Patients after Radiotherapy, a Population-Based Study
Wang R, Zeidan A, Soulos P, Yu J, Davidoff A, Gore S, Gross C, Ma X. Myelodysplastic Syndromes and Acute Myeloid Leukemia in Prostate Cancer Patients after Radiotherapy, a Population-Based Study. Blood 2015, 126: 3295. DOI: 10.1182/blood.v126.23.3295.3295.Peer-Reviewed Original ResearchMDS/AMLProstate cancer patientsIntensity-modulated radiotherapyProstate cancer diagnosisImpact of radiotherapyCancer patientsMyelodysplastic syndromeProstate cancerMyeloid malignanciesSecond malignanciesHazard ratioCancer diagnosisRadiation modalitiesEnd Results-Medicare databaseElderly prostate cancer patientsRisk of MDSMultivariate modelRetrospective cohort studyRole of radiotherapyElixhauser comorbidity scoreAcute myeloid leukemia diagnosisHistory of anemiaAcute myeloid leukemiaEnd of studyExternal beam radiotherapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply